Terms of Access and Use

By downloading, accessing, or viewing material from this website, you agree to the following Terms of Use. The research and analysis provided by Forensic Alpha Limited (“we”, “us”) is for informational and educational purposes only and does not constitute investment advice, a recommendation to buy, sell, or hold any security, or any other form of regulated advice. We do not have, and do not seek to establish, any position (long or short) in the securities discussed in our research.

Our reports present our independent opinions on publicly available information, including but not limited to, company disclosures and financial statements. We aim to highlight potential risks, governance issues, or accounting practices that we believe merit further consideration by market participants. You agree to conduct your own research and due diligence, and to consult your own financial, legal, tax, and other professional advisers before making any investment or business decision. Use of our research is entirely at your own risk. In no event shall Forensic Alpha Limited or any affiliated party be liable for any direct, indirect, incidental, or consequential losses arising from your use of our materials.

The information we provide is based on sources we believe to be accurate and reliable at the time of publication, but it is provided “as is” without any representation or warranty of any kind, whether express or implied, including without limitation as to accuracy, completeness, or fitness for any particular purpose. All opinions expressed are subject to change without notice, and we do not undertake to update or supplement our research.

Access to our research is intended only for persons who are professional investors, institutional investors, or otherwise qualified to receive such information under applicable laws in their jurisdiction. In the United Kingdom, this includes (but is not limited to) persons falling within one or more of the categories described in Articles 19 (Investment Professionals) and 49 (High Net Worth Companies, Unincorporated Associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. By proceeding to access our materials, you confirm that you meet the relevant criteria in your jurisdiction and are legally permitted to receive such information.

All content on this site is the intellectual property of Forensic Alpha Limited and is protected by applicable copyright laws. You agree not to reproduce, distribute, or transmit our research, in whole or in part, without our prior written consent, except by sharing a direct link to our website.

By clicking “I Agree” below, you confirm that you have read and agree to Forensic Alpha Limited’s Terms of Access and Use, that you are a professional or institutional investor (or otherwise qualified under the laws of your jurisdiction to receive such information), and that you understand our research does not constitute investment advice or a recommendation to buy, sell, or hold any security.
I Agree
back arrow

aberdeen: Asset Growth (of the Wrong Kind)

Thomas Beevers
Thomas Beevers
May 13, 2026
Copied!
share button icon

aberdeen: Asset growth (of the wrong kind)

Despite the recovery in the shares, our system continues to identify a number of accounting flags at aberdeen group. Foremost amongst these is the ‘accrued income’ balance, which has continued to rise from what we already flagged as a high level in 2023. Since this balance is only disclosed once per year in the annual report, we haven’t been able to update our thesis until the publication of the 2024 annual report this week.

As explained in our previous note, accrued income arises when fee income is recognized but where the amount has not yet been billed to the customer. Because asset management has a short billing cycle (monthly or quarterly), it’s unusual to see large balances of accrued income build up. This raises the question of whether aberdeen has been aggressive with revenue recognition by recognizing revenue early and ‘parking it’ on the balance sheet. As KPMG mentioned in their audit report last year “the nature and complexity of management fee calculations has increased year on year”. That complexity can create opportunity.

The extract from the 2024 annual report below shows accrued income rising from £310m to £333m, an increase of 7%. What’s concerning about this is that it has risen in a year where management and performance fees have declined by 11%.  The value on the balance sheet of £333m now compares to management and performance fees in 2024 of £815m. That’s equivalent to nearly 5 months of fees.

Over the past 4 years in fact, we’ve seen accrued income rise every year even as fee income has declined every year. Our updated chart below shows fees falling from £1.3bn in 2021 to £815m while accrued income has risen from £260m to £329m.

Note also the disclosure below the table (underlined in red) that the ‘amount of receivables and other financial assets expected to be recovered after more than 12 months is £84m”. This amount has grown from just £34m in FY22. This begs the question of why such a high proportion of these receivables won’t be paid out in the next 12 months (again, consider that asset management normally has a very short billing cycle).

As mentioned previously, aberdeen is under great pressure to demonstrate a successful turnaround, by stabilizing revenues while reducing costs. At the same time the company has experienced a huge amount of management churn, with three different CFOs over the past 18 months. Investors should be aware that this kind of pressure, combined with turnover of management can create an even more fertile environment for accounting problems to arise.

If you are an institutional investor, you can sign up to our email list here
arrow icon
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Institutional investors are eligible for a 7-day free trial.

Our machine intelligence helps Portfolio Managers to spot critical red flags hidden deep within the financial statements and governance disclosures.

Request Demo

Forensic Alpha uses proprietary machine intelligence to identify risks hidden deep within the financial statements and governance disclosures.

Forensic Alpha Limited
Level 39, One Canada Square
Canary Wharf
London E14 5AB

Forensic Alpha US INC
12 East 49th Street
New York
NY 10017
USA

forensic alpha
Forensic Alpha Limited
Level 39, One Canada Square
Canary Wharf
London E14 5AB
Forensic Alpha US INC
12 East 49th Street
New York NY 10017
USA
Forensic Alpha Limited is authorised and regulated by the Financial Conduct Authority (Reference number: 763770)
© 2022 Forensic Alpha. All rights reserved.  Terms & Conditions  |  Privacy Policy  |  Cookie policy
twitter profilelinkedin profile